NCT01781026View on ClinicalTrials.gov

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

PHASE2CompletedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Melanoma

Interventions

DRUG

Vemurafenib

Single arm trial

Trial Locations (1)

06510

Smilow Cancer Hospital at Yale New Haven, New Haven

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Yale University

OTHER